Epithelial to Mesenchymal Transition: A Mechanism that Fuels Cancer Radio/Chemoresistance
Open accessThe DOI matches its Crossref record; 136 of the 137 references it cites were found in a registry or an index.
Abstract
Epithelial to mesenchymal transition (EMT) contributes to tumor progression, cancer cell invasion, and therapy resistance. EMT is regulated by transcription factors such as the protein products of the SNAI gene family, which inhibits the expression of epithelial genes. Several signaling pathways, such as TGF-beta1, IL-6, Akt, and Erk1/2, trigger EMT responses. Besides regulatory transcription factors, RNA molecules without protein translation, micro RNAs, and long non-coding RNAs also assist in the initialization of the EMT gene cluster. A challenging novel aspect of EMT research is the investigation of the interplay between tumor microenvironments and EMT. Several microenvironmental factors, including fibroblasts and myofibroblasts, as well as inflammatory, immune, and endothelial cells, induce EMT in tumor cells. EMT tumor cells change their adverse microenvironment into a tumor friendly neighborhood, loaded with stromal regulatory T cells, exhausted CD8+ T cells, and M2 (protumor) macrophages. Several EMT inhibitory mechanisms are instrumental in reversing EMT or targeting EMT cells. Currently, these mechanisms are also significant for clinical use.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Figure 1 Main EMT regulatory mechanisms. EMT is a product of internal and external events in cells. It is mainly induced by external factors, such as TGF-β1, neurotrophins, or interleukin-6, which activate several signaling pathways such as WNT, Smads, STATs, Akt, or Erk1/2. The activated pathways drive transcription factors (Goosecoid, Snail, Slug, Twist, nuclear factor erythroid-2-related factor 2 (NRF2), and Krüppel-like factors (KLFs)) to bind to special responding sequences in DNA, and, consequently, these mainly suppress the expression of genes related to epithelial differentiation. The best-known event in this process is the down-regulation of E-cadherin by the SNAI transcription factors, Snail, and Slug. At the same time, mesenchymal gene products, such as vimentin, are induced during the transcriptional changes in the EMT process, where the Smad, HIF-1α, and KLF4 transcription factors are directly involved [43,44]. The transcription regulatory process during EMT does not only rely on transcription factors, but also on long noncoding RNAs (lncRNAs) and microRNAs. The external EMT-inducing factors, such as TGF-β1, neurotrophins, or interleukin-6, are available from the fibroblastic and inflammatory microenvironment, but tumor cells also actively participate in the completion of an EMT program [45]. Based on the experimental data of several research groups, including ours, it has been found that acidic extracellular conditions and, in a further step, a low oxygen tension (hypoxia) are necessary for EMT. Interestingly, EMT tumor cells produce immune checkpoint regulatory molecules and actively remodel their immune microenvironment into a more tumor-friendly one from a hostile neighborhood.](https://figures.cochat.ai/paper-figures/d094b8bd283a4ef386664d3b8450b072/epithelial-to-mesenchymal-transition-a-mechanism-that-fuels-cancer-radio-figure-1.jpg)
![Figure 2 The TGF-β1 gradient causes heterogeneity in the tumor cell nests. There are higher TGF-β1 concentrations near the tumor vasculature, and the tumor cell nest has a decreasing gradient from its border towards the middle, which generates heterogeneity between the tumor–stroma interface and the tumor cell nest center [47]. The TGF-β1 gradient contributes to the heterogenic architecture of the tumor cell nest, where the invasive front has a completely different functional and differentiation profile than the core of the tumor cell nest. Additionally, at the invasive front, tumor cells interact with fibroblasts, leukocytes, and other stromal cells. Some scattered tumor cells undergo EMT at the tumor cell nest–stroma interface and contain both epithelial and mesenchymal markers. The figure is based on a figure published by Mayorca-Giuliani and Erler [48], which has been updated by the published data of Nieto et al. [29].](https://figures.cochat.ai/paper-figures/38bb690ce5c7436d87781e26d39438ba/epithelial-to-mesenchymal-transition-a-mechanism-that-fuels-cancer-radio-figure-2.jpg)


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“These include altered drug transport, e.g., overexpression of drug efflux pumps like ABC transporters, activation of cell survival signaling pathways such as PI3K/AKT, and deregulation of apoptotic pathways leading to resistance to apoptosis [76].”
From Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer (2025) · cites this paper as [76]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590 · cited 1×
“Tumor-associated chronic inflammation is a hallmark of cancer [72], which fosters the progression to metastasis [37].”
BackgroundNieto, M. A., Huang, R. Y.-J., Jackson, R. A., & Thiery, J. P. (2016) · Cell · doi:10.1016/j.cell.2016.06.028 · Cited by 4,492
Gregory, P. A., Bert, A. G., Paterson, E. L., Barry, S. C., Tsykin, A., Farshid, G., Vadas, M. A., Khew-Goodall, Y., & Goodall, G. J. (2008) · Nature Cell Biology · doi:10.1038/ncb1722 · Cited by 3,863
Cano, A., Pérez-Moreno, M. A., Rodrigo, I., Locascio, A., Blanco, M. J., del Barrio, M. G., Portillo, F., & Nieto, M. A. (2000) · Nature Cell Biology · doi:10.1038/35000025 · Cited by 3,668
Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma
Hugo, W., Zaretsky, J. M., Sun, L., Song, C., Moreno, B. H., Hu-Lieskovan, S., Berent-Maoz, B., Pang, J., Chmielowski, B., Cherry, G., et al. (2016) · Cell · doi:10.1016/j.cell.2016.02.065 · Cited by 3,448
Epithelial-Mesenchymal Transition: At the Crossroads of Development and Tumor Metastasis
Yang, J., & Weinberg, R. A. (2008) · Developmental Cell · doi:10.1016/j.devcel.2008.05.009 · Cited by 3,012 · cited 1×
“The E-cadherin promoter is hypermethylated in leukemia, which leads to the loss of this protein [56], as in the tumor cells of solid tumors, which can lose E-cadherin by down-regulating EMT [24].”
BackgroundEMT, CSCs, and drug resistance: the mechanistic link and clinical implications
Shibue, T., & Weinberg, R. A. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.44 · Cited by 2,539 · cited 1×
“Nevertheless, the EMT-TFs play even more important pleiotropic roles [4] in invasive, disseminating, and progressive cancer.”
BackgroundZheng, X., Carstens, J. L., Kim, J., Scheible, M., Kaye, J., Sugimoto, H., Wu, C.-C., LeBleu, V. S., & Kalluri, R. (2015) · Nature · doi:10.1038/nature16064 · Cited by 2,032 · cited 4×
“One option to obtain better proof is the identification of EMT cells in tumor tissue sections by selective, reliable, and sensitive immunolabelling [30].”
BackgroundInfluentialBrabletz, T., Kalluri, R., Nieto, M. A., & Weinberg, R. A. (2018) · Nature Reviews Cancer · doi:10.1038/nrc.2017.118 · Cited by 1,961 · cited 9×
“Importantly, both directions of trans-differentiation are reactivated in many cancer types, but a full transition from an epithelial starting point into a differentiated fibroblastic endpoint with the expression of a fibroblast surface protein or vimentin is rarely executed [2,3].”
BackgroundInfluentialStructure of P-Glycoprotein Reveals a Molecular Basis for Poly-Specific Drug Binding
Aller, S. G., Yu, J., Ward, A., Weng, Y., Chittaboina, S., Zhuo, R., Harrell, P. M., Trinh, Y. T., Zhang, Q., Urbatsch, I. L., et al. (2009) · Science · doi:10.1126/science.1168750 · Cited by 1,929 · cited 1×
“EMT cells overexpress the ABC transporters [97,98].”
Cited by
The molecular mechanisms and therapeutic strategies of EMT in tumor progression and metastasis
Huang, Y., Hong, W., & Wei, X. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01347-8 · Cited by 1,032
Dynamic EMT: a multi‐tool for tumor progression
Brabletz, S., Schuhwerk, H., Brabletz, T., & Stemmler, M. P. (2021) · The EMBO Journal · doi:10.15252/embj.2021108647 · Cited by 761
“EMT activation in these cells is controlling therapy resistance on multiple levels (Singh & Settleman, 2010; Shibue & Wein-berg, 2017; Santamaria et al , 2019; Dudas et al , 2020).”
InfluentialTargeting macrophages in cancer immunotherapy
Duan, Z., & Luo, Y. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00506-6 · Cited by 625
Erin, N., Grahovac, J., Brozovic, A., & Efferth, T. (2020) · Drug Resistance Updates · doi:10.1016/j.drup.2020.100715 · Cited by 527
Tumor-associated macrophages in cancer: recent advancements in cancer nanoimmunotherapies
Kumari, N., & Choi, S. H. (2022) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-022-02272-x · Cited by 315
“Another mechanism underpinning chemoresistance has been discovered to be the epithelial to mesenchymal transition, which can be triggered by macrophages [101, 102].”
BackgroundCSC Radioresistance: A Therapeutic Challenge to Improve Radiotherapy Effectiveness in Cancer
Olivares-Urbano, M. A., Griñán-Lisón, C., Marchal, J. A., & Núñez, M. I. (2020) · Cells · doi:10.3390/cells9071651 · Cited by 246
Pericytes in the tumor microenvironment
Jiang, Z., Zhou, J., Li, L., Liao, S., He, J., Zhou, S., & Zhou, Y. (2023) · Cancer Letters · doi:10.1016/j.canlet.2023.216074 · Cited by 175
A gene regulatory network to control EMT programs in development and disease
Fazilaty, H., Rago, L., Youssef, K. K., Ocaña, O. H., García-Asencio, F., Arcas, A., Galcerán, J., & Nieto, M. A. (2019) · Nature Communications · doi:10.1038/s41467-019-13091-8 · Cited by 148
Yu, M. R., Kim, H. J., & Park, H. R. (2020) · Cancers · doi:10.3390/cancers12102728 · Cited by 90
Sayyed, A. A., Gondaliya, P., Mali, M., Pawar, A., Bhat, P., Khairnar, A., Arya, N., & Kalia, K. (2021) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.1c00213 · Cited by 87
Pang, X., Zhang, J., Xu, H., Gu, Y., Qian, B., Xie, R., Yu, W., Zhang, X., Li, T., Shi, X., et al. (2021) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2021/5806602 · Cited by 93
“There are also explicit evidences indicating that EMT may be an important driving factor leading to drug resistance and disease recurrence [15].”
BackgroundInfluentialPhotodynamic therapy regulates fate of cancer stem cells through reactive oxygen species
Zhang, Z., Wang, K., Mo, J., Xiong, L., & Wen, Y. (2020) · World Journal of Stem Cells · doi:10.4252/wjsc.v12.i7.562 · Cited by 86
Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer
Haynes, J., & Manogaran, P. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26051988 · Cited by 82
“These include altered drug transport, e.g., overexpression of drug efflux pumps like ABC transporters, activation of cell survival signaling pathways such as PI3K/AKT, and deregulation of apoptotic pathways leading to resistance to apoptosis [76].”
Sun, T., Kang, Y., Liu, J., Zhang, Y., Ou, L., Liu, X., Lai, R., & Shao, L. (2021) · Journal of Nanobiotechnology · doi:10.1186/s12951-021-00843-2 · Cited by 75
El‐Mahdy, H. A., Elsakka, E. G. E., El-Husseiny, A. A., Ismail, A., Yehia, A. M., Abdelmaksoud, N. M., Elshimy, R. A. A., Noshy, M., & Doghish, A. S. (2023) · Pathology - Research and Practice · doi:10.1016/j.prp.2023.154316 · Cited by 69
Regulation of T cells by myeloid-derived suppressor cells: emerging immunosuppressor in lung cancer
He, Z., Zhang, C., Zhao, Y., He, S., Li, Y., Shi, B., Hu, J., Qi, R., & Hua, B. (2023) · Discover Oncology · doi:10.1007/s12672-023-00793-1 · Cited by 76
“MDSCs can inhibit T-cell immune functions in various ways, and the EMT process mediated by MDSCs is linked to the reduction of CD4 + and CD8 + T cells in the TME, recruitment of Tregs, and the exhaustion of T cells [131, 132].”
BackgroundRoles of S100 family members in drug resistance in tumors: Status and prospects
Hua, X., Zhang, H., Jia, J., Chen, S., Sun, Y., & Zhu, X. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110156 · Cited by 62
Liu, K., Sun, Q., Liu, Q., Li, H., Zhang, W., & Sun, C. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113618 · Cited by 59
Doghish, A. S., El-Husseiny, A. A., Abdelmaksoud, N. M., El‐Mahdy, H. A., Elsakka, E. G. E., Mageed, S. S. A., Mahmoud, A. M. A., Raouf, A. A., Elballal, M. S., El‐Dakroury, W. A., et al. (2023) · Pathology - Research and Practice · doi:10.1016/j.prp.2023.154529 · Cited by 56
Khan, A. Q., Hasan, A., Mir, S. S., Rashid, K., Shahab Uddin, M. S., & Steinhoff, M. S. (2024) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2024.03.002 · Cited by 69
The role of macrophages in the tumor microenvironment and tumor metabolism
Sadhukhan, P., & Seiwert, T. Y. (2023) · Seminars in Immunopathology · doi:10.1007/s00281-023-00988-2 · Cited by 53
Rajput, M., Singh, R., Singh, N., & Singh, R. P. (2021) · Life Sciences · doi:10.1016/j.lfs.2021.120031 · Cited by 50
Schiavoni, V., Emanuelli, M., Milanese, G., Galosi, A. B., Pompei, V., Salvolini, E., & Campagna, R. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252413239 · Cited by 52
Ritter, A., Kreis, N., Roth, S., Friemel, A., Safdar, B. K., Hoock, S. C., Wildner, J. M., Allert, R., Louwen, F., Solbach, C., et al. (2023) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-022-02592-y · Cited by 47
Pawar, J. S., Salam, M. A., Dipto, M. S. U., Al-Amin, M. Y., Salam, M. T., Sengupta, S., Kumari, S., Gujjari, L., & Yadagiri, G. (2025) · Cancers · doi:10.3390/cancers17152484 · Cited by 49
“…into CAFs through endothelial–mesenchymal transition [40]; E. EMT— epithelial cells are transformed into CAFs through epithelial–mesenchymal transition [41]; F. MMT— monocytes are transformed into CAFs through monocyte–myofibroblast transdifferentiation [42] (created with BioRender.com icons).”
Biological and Clinical Aspects of Metastatic Spinal Tumors
Litak, J., Czyżewski, W., Szymoniuk, M., Sakwa, L., Pasierb, B., Litak, J., Hoffman, Z., Kamieniak, P., & Roliński, J. (2022) · Cancers · doi:10.3390/cancers14194599 · Cited by 43
Resveratrol and Its Analogs: Potent Agents to Reverse Epithelial-to-Mesenchymal Transition in Tumors
Guo, K., Feng, Y., Zheng, X., Sun, L., Wasan, H. S., Ruan, S., & Shen, M. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.644134 · Cited by 43
“EMT participates not only in the cancer metastasis but also in the appearance of chemoresistance (98).”
BackgroundEngaging plasticity: Differentiation therapy in solid tumors
Bar-Hai, N., & Ishay-Ronen, D. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.944773 · Cited by 35
“Therapeutic approaches to overcome cancer cell plasticity can be broadly divided to three categories; preventing cell plasticity (Gupta et al., 2009; Al-Lazikani et al., 2012; Pecot et al., 2013; Proffitt et al., 2013; Cortez et al., 2014; Smith et al., 2014; Wilson et al., 2014; Meidhof et al., 2015; Zhang et al., 20…”
BackgroundChemoresistance: The hidden barrier in cancer treatment
Dhiman, V. K., Kumari, M., & Singh, D. (2025) · Cancer Pathogenesis and Therapy · doi:10.1016/j.cpt.2025.07.001 · Cited by 51
“39 Furthermore, EMT has been linked to the acquisition of cancer stem cell (CSC) properties, enabling tumor cells to self-renew and resist conventional therapies.”
Lee, P. W. T., Koseki, L. R., Haitani, T., Harada, H., & Kobayashi, M. (2024) · Cancers · doi:10.3390/cancers16091729 · Cited by 42
Jiang, L., Zhang, Y., Su, P., Ma, Z., Ye, X., Kang, W., Liu, Y., & Yu, J. (2022) · Translational Oncology · doi:10.1016/j.tranon.2022.101351 · Cited by 35
Role of the KEAP1-NRF2 Axis in Renal Cell Carcinoma
Clerici, S., & Boletta, A. (2020) · Cancers · doi:10.3390/cancers12113458 · Cited by 38
TSPAN1: A Novel Protein Involved in Head and Neck Squamous Cell Carcinoma Chemoresistance
Garcia‐Mayea, Y., Mir, C., Carballo-Perich, L., Castellví, J., Temprana‐Salvador, J., Lorente, J., Benavente, S., Garcia-Pedrero, J. M., Allonca, E., Rodrigo, J. P., et al. (2020) · Cancers · doi:10.3390/cancers12113269 · Cited by 37
Chen, S., Shen, J., Zhao, J., Wang, J., Shan, T., Li, J., Xu, M., Chen, X., Liu, Y., & Cao, G. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.597672 · Cited by 30
Hariri, A., Mirian, M., Khosravi, A., Zarepour, A., Iravani, S., & Zarrabi, A. (2024) · Drug Resistance Updates · doi:10.1016/j.drup.2024.101119 · Cited by 31
Wiecheć, E., Matić, N., Ali, A., & Roberg, K. B. (2022) · Oncology Reports · doi:10.3892/or.2022.8269 · Cited by 29
“In a majority of tumors, including HNSCC, EMT is tightly linked to hypoxia, leading to an increased radioresistance (18,19).”
Bong, J. W., Gim, J., Ju, Y., Cheong, C., Lee, S.-I., Oh, S.-C., Min, B.-W., & Kang, S. (2022) · Cancers · doi:10.3390/cancers14051297 · Cited by 35
Bano, A., Vats, R., Yadav, P., & Bhardwaj, R. (2022) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2022.103799 · Cited by 27
A Systematic Review on Organ-on-a-Chip in PDMS or Hydrogel in Dentistry: An Update of the Literature
Pierfelice, T. V., D’Amico, E., Petrini, M., Romano, M., D’Arcangelo, C., Sbordone, L., Barone, A. A., Plebani, R., & Iezzi, G. (2024) · Gels · doi:10.3390/gels10020102 · Cited by 30
Sun, M., An, H., Sun, Y.-B., Sun, Y., & Bai, B. (2022) · Journal of Orthopaedic Surgery and Research · doi:10.1186/s13018-022-03449-y · Cited by 24
Ingruber, J., Dudás, J., Savic, D., Schweigl, G., Steinbichler, T. B., Greier, M. D. C., Santer, M., Carollo, S., Trajanoski, Z., & Riechelmann, H. (2022) · Experimental Cell Research · doi:10.1016/j.yexcr.2022.113084 · Cited by 28
Self-citationYadav, P., Rajendrasozhan, S., Lajimi, R. H., Patel, R. R., Heymann, D., & Prasad, N. R. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1494723 · Cited by 26
“Metastatic cancer cells predominantly demonstrate the EMT phenomenon that contributes greatly to the progression of malignant cells and resistance to chemotherapy (94, 95).”
Sulforaphene inhibits the progression of osteosarcoma via regulating FSTL1/NF-κB pathway
Zhang, G., Jin, C., Zhu, Y., Fu, F., Wang, G., & Li, S. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.118485 · Cited by 22
Xu, F., Yan, J., Peng, Z., Liu, J., & Li, Z. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1096009 · Cited by 22
“revealed that epithelial-mesenchymal transition (EMT) was vital in tumor progression and metastasis (26).”
BackgroundLoss of p53 epigenetically modulates epithelial to mesenchymal transition in colorectal cancer
Sharma, S., Rani, H., Mahesh, Y., Jolly, M. K., Dixit, J., & Mahadevan, V. (2024) · Translational Oncology · doi:10.1016/j.tranon.2023.101848 · Cited by 23
Alalhareth, I. S., Alyami, S. M., Alshareef, A. H., Ajeibi, A. O., Munjem, M. F. A., Elfifi, A. A., Alsharif, M. M., Alzahrani, S. A., Alqaad, M. A., Bakir, M. B., et al. (2025) · Pharmaceuticals · doi:10.3390/ph18020207 · Cited by 24
Liang, R., Zhang, J., Liu, Z., Liu, Z., Li, Q., Luo, X., Li, Y., Ye, J., & Lin, Y. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2020.585452 · Cited by 20
Targeting cancer-associated fibroblasts with pirfenidone: A novel approach for cancer therapy
Rastegar‐Pouyani, N., Abdolvahab, M. H., Farzin, M. A., Zare, H., Kesharwani, P., & Sahebkar, A. (2024) · Tissue and Cell · doi:10.1016/j.tice.2024.102624 · Cited by 25
Rajagopal, M. U., Bansal, S., Kaur, P., Jain, S. K., Altadill, T., Hinzman, C. P., Li, Y., Moulton, J., Singh, B. B., Bansal, S., et al. (2021) · Cancers · doi:10.3390/cancers13246204 · Cited by 20
“Epithelial-to-mesenchymal transition (EMT) has been extensively reported to contribute pathologically to fibrosis and cancer progression and reported as a key priming event for tumor development [37].”
BackgroundDavies, C. R., Guo, T., Burke, E., Stankiewicz, E., Xu, L., Mao, X., Scandura, G., Rajan, P., Tipples, K., Alifrangis, C., et al. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2022.1060864 · Cited by 20
Lusby, R., Zhang, Z., Mahesh, A., & Tiwari, V. K. (2024) · npj Precision Oncology · doi:10.1038/s41698-024-00529-6 · Cited by 26
“1d), processes associated with EMT, con fi rming the results from Kim et al. and which have previously been implicated in TNBC chemoresistance 23 .”
Ancel, J., Dewolf, M., Deslée, G., Nawrocki‐Raby, B., Dalstein, V., Gilles, C., & Polette, M. (2020) · Cells Tissues Organs · doi:10.1159/000510103 · Cited by 23
“EMT in Advanced and Metastatic Lung Cancers In addition to promoting local and distant dissemina- tion/recurrence, EMT was proposed by many authors to support resistance to therapies [Dudas et al., 2020].”
BackgroundMoon, S.-H., Ok, Y.-J., Hwang, S.-Y., Lim, Y. S., Kim, H.-Y., Na, Y.-J., & Yoon, S. (2020) · Marine Drugs · doi:10.3390/md18100498 · Cited by 22
“Multiple lines of evidence have established that epithelial–mesenchymal transition (EMT) is vital in tumor growth, progression, invasion, dissemination, metastasis, and drug resistance [39,40].”
BackgroundProneural-mesenchymal antagonism dominates the patterns of phenotypic heterogeneity in glioblastoma
Harshavardhan, B. V., & Jolly, M. K. (2024) · iScience · doi:10.1016/j.isci.2024.109184 · Cited by 18
“3,36,37 Consistently, recurrent GBMs are enriched in a mesenchymal state.”
BackgroundWu, Y., Huang, C.-S., Hsieh, M., Huang, C.-M., Setiawan, S. A., Yeh, C., Kuo, K.-T., & Liu, S. (2024) · Aging · doi:10.18632/aging.205409 · Cited by 36
Reschke, R., Deitert, B., Enk, A., & Hassel, J. C. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1385781 · Cited by 22
Anthrahydroquinone-2-6-disulfonate is a novel, powerful antidote for paraquat poisoning
Qian, J., Wu, C., Wu, D., Li, L., Li, Q., Deng, T., Huang, Q.-F., Xu, S.-Q., Wang, H.-F., Wu, X., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-99591-4 · Cited by 19
Lv, N., Liu, F., Cheng, L., Liu, F., & Kuang, J. (2021) · Journal of Cancer · doi:10.7150/jca.53349 · Cited by 20
“Often the expression of Snail family genes Snail, Slug and other E-cadherin repressors such as Zeb1, Zeb2 and Twist1 can be detected at sites of EMT in the leading edge of an invading tumour by immunohistochemically technique [5].”
BackgroundAn overview of the intracellular localization of high-Z nanoradiosensitizers
Varzandeh, M., Labbaf, S., Varshosaz, J., & Laurent, S. (2022) · Progress in Biophysics and Molecular Biology · doi:10.1016/j.pbiomolbio.2022.08.006 · Cited by 17
“Epithelial-mesenchymal transition (EMT) is a principal route that induces metastatic cancers and plays a role as a radio-resistance element (Dud ´ as et al., 2020).”
BackgroundSun, X., Li, H., Xie, D.-F., Gao, S., Huang, X., Guan, H., Bai, C., & Zhou, P. (2022) · Journal of Translational Medicine · doi:10.1186/s12967-022-03673-4 · Cited by 18
Xu, R., He, S., Ma, D., Liang, R., Luo, Q., & Song, G. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms24010073 · Cited by 17
Dogra, S., Elayapillai, S. P., Qu, D., Pitts, K., Filatenkov, A., Houchen, C. W., Berry, W. L., Moxley, K. M., & Hannafon, B. N. (2023) · Cancer Letters · doi:10.1016/j.canlet.2023.216437 · Cited by 18
Alhattab, D. M., Isaioglou, I., Alshehri, S., Khan, Z. N., Susapto, H. H., Li, Y., Marghani, Y., Alghuneim, A. A., Díaz‐Rúa, R., Abdelrahman, S., et al. (2023) · Biomaterials Research · doi:10.1186/s40824-023-00457-9 · Cited by 21
“The EMT pathway has been reported in solid tumors for cancer metastasis and drug resistance [100].”
BackgroundThe related miRNAs involved in doxorubicin resistance or sensitivity of various cancers: an update
Torki, Z., Ghavi, D., Hashemi, S., Rahmati, Y., Rahmanpour, D., Pornour, M., & Alivand, M. R. (2021) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-021-04337-8 · Cited by 17
Epithelial-to-Mesenchymal Transition Drives Invasiveness of Breast Cancer Brain Metastases
Margarido, A. S., Uceda-Castro, R., Hahn, K., de Bruijn, R., Kester, L. A., Hofland, I., Lohuis, J. O., Seinstra, D., Broeks, A., Jonkers, J., et al. (2022) · Cancers · doi:10.3390/cancers14133115 · Cited by 18
Vitaliti, A., Roccatani, I., Iorio, E., Perta, N., Gismondi, A., Chirico, M., Pisanu, M. E., Marino, D. D., Canini, A., Luca, A. D., et al. (2022) · Cellular Oncology · doi:10.1007/s13402-022-00738-w · Cited by 18
Zhang, B., Wang, S., Fu, Z., Gao, Q., Yang, L., Lei, Z., Shi, Y., Le, K., Xiong, J., Liu, S., et al. (2023) · Frontiers in Genetics · doi:10.3389/fgene.2022.1073232 · Cited by 20
“Emerging evidence demonstrates that the EMT process can promote tumor cell invasion and metastasis by loss of cellcell connections and cell polarity (Dudas et al., 2020).”
BackgroundRezouki, I., Zohair, B., Ssi, S. A., Karkouri, M., Razzouki, I., Elkarroumi, M., & Badou, A. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1154631 · Cited by 19
“EMT is mainly maintained by tumor tissue inflammation, impeding consequently the antitumor immune response through inhibitory immune checkpoint activation (9, 12).”
BackgroundTraberg, W. C., Uribe, J., Druet, V., Hama, A., Moysidou, C., Huerta, M., McCoy, R. S. A., Hayward, D., Savva, A., Genovese, A. M. R., et al. (2023) · Advanced Healthcare Materials · doi:10.1002/adhm.202301194 · Cited by 14
Role of Microenvironmental Components in Head and Neck Squamous Cell Carcinoma
Jumaniyazova, E. D., Lokhonina, А. V., Dzhalilova, D. S., Kosyreva, A. M., & Fatkhudinov, T. (2023) · Journal of Personalized Medicine · doi:10.3390/jpm13111616 · Cited by 22
“…in the synthesis and degradation of ECM components, are responsible for ensuring the structural integrity of most tissues, produce basement membrane components that provide a protective barrier around epithelial tissue, and determine the polarity and functioning of epithelial cells [92,93].”
BackgroundMechanisms of breast cancer metastasis: the role of extracellular matrix
Chen, R., Zhang, R., Ke, F., Guo, X., Zeng, F., & Liu, Q. (2024) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-024-05175-x · Cited by 21
“Research also indicates that the transition from a mesenchymal to an epithelial state serves as a mechanism for cancer cells to colonize secondary sites [41].”
Cao, Y., Fan, C.-Q., Chen, Y.-X., Guo, F., Rao, H., Che, P.-Y., Zuo, C., & Chen, H.-W. (2025) · Discover Oncology · doi:10.1007/s12672-025-01782-2 · Cited by 20
Aberuyi, N., Rahgozar, S., Pourabutaleb, E., & Ghaedi, K. (2020) · Current Research in Translational Medicine · doi:10.1016/j.retram.2020.09.003 · Cited by 16
Therapeutic Status and Available Strategies in Pancreatic Ductal Adenocarcinoma
Thakur, G., Kumar, R., Kim, S.-B., Lee, S.-Y., Lee, S., & Rho, G. (2021) · Biomedicines · doi:10.3390/biomedicines9020178 · Cited by 23
“It has been shown that EMT plays a key role in cancer cell resistance to traditional chemotherapeutics, including gemcitabine, vincristine, oxaliplatin, and taxol [135].”
BackgroundRiechelmann, H., Steinbichler, T. B., Sprung, S., Santer, M., Runge, A., Ganswindt, U., Gamerith, G., & Dudás, J. (2021) · Cancers · doi:10.3390/cancers13040772 · Cited by 16
Self-citationWu, Y., Ho, J., Yu, C., Cho, C., Wu, C., Huang, C., Gao, H., & Yü, D. (2021) · Cancers · doi:10.3390/cancers13092032 · Cited by 20
Xiao, Z., Cai, Z., Deng, D., Tong, S., & Zu, X. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1000321 · Cited by 19
Wnt/β-catenin signaling pathway: an attractive potential therapeutic target in osteosarcoma
Ding, Y., & Chen, Q. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2024.1456959 · Cited by 20
“Lung metastasis is the most common site of osteosarcoma and the most common cause of death (81).”
CHEK1 : A Hub Gene Related to Poor Prognosis for Lung Adenocarcinoma
Tan, Z., Chen, M., Wang, Y., Peng, F., Zhu, X., Li, X., Zhang, L., Li, Y., & Liu, Y. (2021) · Biomarkers in Medicine · doi:10.2217/bmm-2021-0919 · Cited by 22
Pouliquen, D., Boissard, A., Henry, C., Coqueret, O., & Guette, C. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.934534 · Cited by 18
Radiotherapy and radio‐sensitization in H3K27M ‐mutated diffuse midline gliomas
Liu, C., Kuang, S., Wu, L., Cheng, Q., Gong, X., Wu, J., & Zhang, L. (2023) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.14225 · Cited by 17
LncRNAs and PTEN/PI3K signaling: A symphony of regulation in cancer biology
Almalki, W. H. (2023) · Pathology - Research and Practice · doi:10.1016/j.prp.2023.154764 · Cited by 16
Baba, R. E., Ahmad, S. H., Monnien, F., Mansar, R., Bibeau, F., & Herbein, G. (2023) · Oncogene · doi:10.1038/s41388-023-02813-4 · Cited by 17
“EMT fuels cancer progression, tumor cell invasion, and therapy resistance [35].”
BackgroundID4 predicts poor prognosis and promotes BDNF-mediated oncogenesis of colorectal cancer
Ha, C.-T., Cheng, C., Zheng, M., Hsu, T.-H., Miao, C., Lee, C.-J., Wang, H., Pan, S., & Chou, Y. (2021) · Carcinogenesis · doi:10.1093/carcin/bgab037 · Cited by 15
Le, H. T., Lee, H. J., Cho, J., Min, H.-Y., Lee, J., Lee, J. S., & Lee, S. (2021) · Cancers · doi:10.3390/cancers13051041 · Cited by 17
“Because cancer cell migration is a typical phenotype of the EMT program [31], we determined the role of IGFBP-3 in TGF-βinduced migration.”
BackgroundThe Role of TAMs in the Regulation of Tumor Cell Resistance to Chemotherapy
McWhorter, R., & Bonavida, B. (2024) · Critical Reviews™ in Oncogenesis · doi:10.1615/critrevoncog.2024053667 · Cited by 14
Song, W. H., Lim, Y. S., Kim, J., Kang, H. Y., Lee, C., Rajbongshi, L., Hwang, S.-Y., Oh, S., Kim, B. S., Lee, D., et al. (2024) · Marine Drugs · doi:10.3390/md22070295 · Cited by 15
FABP4 facilitates epithelial-mesenchymal transition via elevating CD36 expression in glioma cells
You, Z., Hu, Z., Hou, C., Ma, C., Xu, X., Zheng, Y., Sun, X., Ke, Y., Liang, J., Xie, Z., et al. (2024) · Neoplasia · doi:10.1016/j.neo.2024.101050 · Cited by 14
“Previous studies have defined several key molecules including TGF β and Wnt as key inducers in EMT [6].”
Epithelial-to-Mesenchymal Transition and Neoangiogenesis in Laryngeal Squamous Cell Carcinoma
Franz, L., Nicolè, L., Frigo, A. C., Ottaviano, G., Gaudioso, P., Saccardo, T., Visconti, F., Cappellesso, R., Blandamura, S., Fassina, A., et al. (2021) · Cancers · doi:10.3390/cancers13133339 · Cited by 15
Characterization of LncRNA SNHG22 as a protector of NKIRAS2 through miR-4492 binding in osteosarcoma
Zheng, H., Yang, R., Xu, W., Liu, T., Chen, P., Zheng, X., Li, B., Jiang, L., & Jiang, S. (2020) · Aging · doi:10.18632/aging.103849 · Cited by 17
Single-cell tracking as a tool for studying EMT-phenotypes
Quinsgaard, E. M. B., Korsnes, M. S., Korsnes, R., & Moestue, S. A. (2024) · Experimental Cell Research · doi:10.1016/j.yexcr.2024.113993 · Cited by 12
Mitochondrial dysfunction and epithelial to mesenchymal transition in head neck cancer cell lines
Greier, M. C., Runge, A., Dudás, J., Pider, V., Skvortsova, I., Savic, D., & Riechelmann, H. (2022) · Scientific Reports · doi:10.1038/s41598-022-16829-5 · Cited by 14
Self-citationInterplay between Partial EMT and Cisplatin Resistance as the Drivers for Recurrence in HNSCC
Ingruber, J., Dudás, J., Sprung, S., Lungu, B., & Mungenast, F. (2022) · Biomedicines · doi:10.3390/biomedicines10102482 · Cited by 14
“Slug and EMT are related with R(C)T resistance [2,3,8,17].”
BackgroundSelf-citationAlternatively-spliced lncRNA-PNUTS promotes HCC cell EMT via regulating ZEB1 expression
Zhao, H., Liu, C., Zhao, C., Che, C., Liu, W., & Yan, M. (2022) · Tumori Journal · doi:10.1177/03008916211072585 · Cited by 13
Rohan, P., dos Santos, E. C., Abdelhay, E. S. F. W., & Binato, R. (2023) · Genes · doi:10.3390/genes15010028 · Cited by 11
“The EMT process has already been shown to be an important factor in resistance to cancer therapy [75,76].”
BackgroundTsochantaridis, I., Brisimis, D., Tsifintaris, M., Anastasiadou, A., Lazos, E., Ermogenous, A., Christou, S., Antonopoulou, N., Panayiotidis, M. I., Koukourakis, M., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms251910301 · Cited by 11
“The enhanced chemoresistant phenotype of A549/ALDH1B1 cells and the mechanistic link between EMT and chemoresistance [25] prompted us to further investigate the effect of ALDH1B1 on EMT transcription factors and regulators.”
BackgroundWang, X., Qiu, W., Liu, H., Li, T., Ye, H., Li, Y., Xu, X. M., & Chen, P. (2020) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/1440-1681.13408 · Cited by 10
Chałaśkiewicz, K., Karaś, K., Zakłos‐Szyda, M., Karwaciak, I., Pastwińska, J., Koziołkiewicz, M., & Ratajewski, M. (2023) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2023.175728 · Cited by 13
Cosimo, S. D., Verde, N. M. L., Moretti, A., Cazzaniga, M. E., Generali, D., Bianchi, G., Mariani, L., Torri, V., Crippa, F., Paolini, B., et al. (2019) · PLoS ONE · doi:10.1371/journal.pone.0220644 · Cited by 11
Clark, L. E., DICKINSON, A. J. G., & Lima, S. (2023) · Cells · doi:10.3390/cells12141886 · Cited by 11
Metadata
- Authors
- Dudás, J., Ladányi, A., Ingruber, J., Steinbichler, T. B., & Riechelmann, H.
- Affiliations
- Innsbruck Medical University (AT)
- National Institute of Oncology (HU)
- Corresponding author
- Dudás, József
- Venue
- Cells
- Publisher
- MDPI AG
- Published
- 2020-02-12
- Volume
- 9
- Issue
- 2
- Pages
- 428
- ISSN
- 2073-4409 (ISSN-L)
- PMC
- PMC7072371
- OpenAlex
- W3006507687
- Cited by
- 213
- References
- 137
- Citations by year
- 2026: 21 · 2025: 31 · 2024: 41 · 2023: 34 · 2022: 40 · 2021: 28 · 2020: 16
- FWCI
- 3.17
- Type
- journal article
- Language
- en
- Open access
- gold
- dx.doi.org
- Licence
- Locations
- Cells (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Austrian Science Fund (P25869-B13, I3976-B33)
- Nemzeti Kutatási Fejlesztési és Innovációs Hivatal (ANN 128524)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › TGF-β signaling in diseases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Mechanisms of cancer metastasis
- Keywords
- epithelial-mesenchymal transition, cancer therapy resistance, radioresistance (biology), chemoresistance, TGF-β1 signaling, microRNA, long non-coding RNA, tumor microenvironment, cancer-associated fibroblasts, myofibroblasts, regulatory T cells, M2 macrophages, CD8+ T cell exhaustion, EMT reversal
- MeSH terms
- Antineoplastic Agents, Phytogenic, Humans, Neoplasms, Transcription Factors, Signal Transduction, Transforming Growth Factor beta, Drug Resistance, Neoplasm, Mitogen-Activated Protein Kinase 3, T-Lymphocytes, Regulatory, Epithelial-Mesenchymal Transition
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.